Cobas e411 platform

Manufactured by Roche

Sourced in Germany, Switzerland

The Cobas e411 is an automated immunoassay analyzer platform developed by Roche. The core function of the Cobas e411 is to perform immunochemistry tests on biological samples to detect and measure specific analytes. The platform is designed for clinical diagnostic laboratories.

Automatically generated - may contain errors

Lab products found in correlation

Clc 100, by Chromsystems (2 mentions) Elecsys anti sars cov 2 s assay, by Roche (2 mentions) Nmr spectrometer at 400 mhz, by Bruker (1 mentions) Architect ci8200 platform, by Abbott (1 mentions) Api5000 triple quadrupole mass spectrometer, by AB Sciex (1 mentions) Immulite 2000 xpi analyzer, by Siemens (1 mentions) Elecsys anti sars cov 2 n, by Roche (1 mentions) Il 6 elisa kit, by RayBiotech (1 mentions) Cobas 4800, by Roche (1 mentions) Cobas 6800, by Roche (1 mentions) Architect c16000 platform, by Abbott (1 mentions) Cell dyn sapphire platform, by Abbott (1 mentions) Human high sensitivity cytokine base kit a, by R&D Systems (1 mentions) 3 3 5 5 tetramethylbenzidine (tmb), by Thermo Fisher Scientific (1 mentions) 42 plex luminex discovery assay, by Eve Technologies (1 mentions)

15 protocols using cobas e411 platform

Plasma TMAO and Cardiac Troponin Levels

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Informed consent was obtained from all patients and fasting blood samples were collected using EDTA tubes at the time of hospital visit. These were then immediately processed and frozen at − 80 °C until analysis. Plasma TMAO levels were determined using an NMR spectrometer at 400 MHz (Bruker, USA). The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was employed to obtain spectra (recycle delay-90°-t1-90°-tm-90°-acquisition) over 64 scans with four dummy scans. Quantification was achieved using a concentration of a known reference signal (in this case TSP) to determine the TMAO concentration. hs-cTnT was measured using a high-sensitivity (5^th generation) assay on a Roche Cobas e411 platform (Roche Diagnostics, Basel, Switzerland). We defined SMD as hs-cTnT ≥ 14 ng/L, as this is considered the upper limit (the 99^th percentile) of the normal range in the healthy population^{19 (link)}. eGFR was calculated using the modification of diet in renal disease (MDRD) equation.

Senthong V., Kiatchoosakun S., Wongvipaporn C., Phetcharaburanin J., Tatsanavivat P., Sritara P, & Phrommintikul A. (2021). Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand. Scientific Reports, 11, 14963.

+ Open protocol

+ Expand

Plasma TMAO Levels in Cardiac Patients

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

After informed consent was obtained from all patients, fasting blood samples were collected using ethylenediaminetetraacetic acid (EDTA) tubes at the time of cardiac catheterization, which were then immediately processed and frozen at −80° C until analysis. TMAO levels in plasma were determined using stable isotope dilution high-performance liquid chromatography with online tandem mass spectrometry on an API 5000 triple quadrupole mass spectrometer (AB SCIEX, Framingham, Massachusetts), as previously described (12 (link),26 (link)). The assay described shows inter- and intraday reproducibility (all coefficient of variations <7%) and accuracy (>98.5% across low, mid and high values). Routine laboratory tests and high-sensitivity C-reactive protein (hsCRP) were measured using the Architect ci8200 platform (Abbott Laboratories, Abbott Park, Illinois,), high-sensitivity cardiac troponin T (hs-cTnT) was measured by a high-sensitivity (fifth generation) assay on a Roche Cobas e411 platform (Roche Diagnostics, Indianapolis, Indiana). Estimated glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease equation.

Senthong V., Li X.S., Hudec T., Coughlin J., Wu Y., Levison B., Wang Z., Hazen S.L, & Wilson Tang W.H. (2016). Plasma Trimethylamine N-oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, is Associated with Atherosclerotic Burden. Journal of the American College of Cardiology, 67(22), 2620-2628.

+ Open protocol

+ Expand

Biomarker Analysis of Fasting Blood Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were drawn at 8 am after an overnight fasting period and a 20‐minute supine rest.19 NT‐proBNP (N‐terminal proBNP) was measured with the ECLIA monoclonal method using the Cobas e411 platform (Roche Diagnostics). Plasma renin activity and aldosterone were assayed using a radioimmunoassay method.20, 21 Plasma norepinephrine and epinephrine were evaluated by means of high‐performance liquid chromatography using the electrochemical detector CLC 100 (Chromsystems). Assays were performed according to manufacturer instructions.

Vergaro G., Ghionzoli N., Innocenti L., Taddei C., Giannoni A., Valleggi A., Borrelli C., Senni M., Passino C, & Emdin M. (2019). Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8(20), e013441.

+ Open protocol

+ Expand

Comprehensive Immune Profiling in Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood was obtained by venipuncture from all the patients on admission. We have analyzed: Complete Blood Count (CBC) and immune-inflammatory parameters: interleukin-6, procalcitonin (PCT), C-reactive protein (CRP), soluble-IL2 receptor (IL2Rα) and ferritin.
CBC was performed by the hematology analyzer Convergys 3X®. IL6, CRP and IL2Rα were measured by chemiluminescence immunoassay (CLIA) via IMMULITE® 2000 XPI analyzer (Siemens). The fully automated electrochemiluminescence method (ECLIA) was used to measure levels of PCT and ferritin on COBAS® E411 platform (Roche Diagnostics).

Sayah W., Berkane I., Guermache I., Sabri M., Lakhal F.Z., Yasmine Rahali S., Djidjeli A., Lamara mahammed L., Merah F., Belaid B., Berkani L., Lazli N.Z., Kheddouci L., Kadi A., Ouali M., Khellafi R., Mekideche D., Kheliouen A., Hamidi R.M., Ayoub S., Raaf N.B., Derrar F., Gharnaout M., Allam I, & Djidjik R. (2021). Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. Cytokine, 141, 155428.

+ Open protocol

+ Expand

Cardiovascular Biomarker Assessment in Heart Failure

Check if the same lab product or an alternative is used in the 5 most similar protocols

The baseline information included demographics, laboratory test results, mortality, and other clinical variables. Blood samples were collected in the early morning after overnight fasting.¹⁰ N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) was measured with the electro chemo luminescent immunoassay (ECLIA) monoclonal method using the Cobas e411 platform (Roche Diagnostics). The LVEF measurements were performed with the same standard by senior echocardiography physicians, who were responsible for data quality control and periodical data verification. The reading was standardized and consistent across years.

Chen S., Huang Z., Liang Y., Zhao X., Aobuliksimu X., Wang B., He Y., Kang Y., Huang H., Li Q., Yao Y., Lu X., Qian X., Xie X., Liu J, & Liu Y. (2022). Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. ESC Heart Failure, 9(4), 2336-2347.

+ Open protocol

+ Expand

Quantitative SARS-CoV-2 Antibody Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The Elecsys Anti-SARS-CoV-2 S assay (Roche, Penzberg, Germany) is a commercially available immunoassay using a recombinant RBD of the S-Antigen representing protein for the quantitative determination of high-affinity antibodies to SARS-CoV-2 on a Roche cobas e411 platform. For quantitative determination of IgG, data were expressed in Units per ml (U/ml). Values smaller than 0.8 U/ml were interpreted as negative for anti-SARS-CoV-2 antibodies and positive otherwise following the manufacturers’ instructions.

Schramm R., Costard-Jäckle A., Rivinius R., Fischer B., Müller B., Boeken U., Haneya A., Provaznik Z., Knabbe C, & Gummert J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clinical Research in Cardiology, 110(8), 1142-1149.

+ Open protocol

+ Expand

Electrochemiluminescence Assay for SARS-CoV-2 Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols

The anti-spike antibody titer was measured using the Elecsys anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd., Basel, Switzerland), which is an electrochemiluminescence immunoassay with a double-antigen sandwich design used to detect immunoglobulins in the RBD of the spike protein. This kit primarily detects IgG, IgA, and IgM. Serum samples were prepared according to the manufacturer’s instructions and analyzed using the Roche Cobas e411 platform. According to the manufacturer’s guidelines, sample values of ≥0.8 AU/mL were classified as positive for anti-SARS-CoV-2 antibodies.

Seki Y., Yoshihara Y., Nojima K., Momose H., Fukushi S., Moriyama S., Wagatsuma A., Numata N., Sasaki K., Kuzuoka T., Yato Y., Takahashi Y., Maeda K., Suzuki T., Mizukami T, & Hamaguchi I. (2022). Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med (New York, N.y.), 3(6), 406-421.e4.

+ Open protocol

+ Expand

Anti-N Seropositive Detection Using ECLIA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-N seropositive was investigated using the electrochemiluminescence immunoassay (ECLIA) (Elecsys® Anti-SARS-CoV-2 N, Roche Diagnostics GmbH, Mannheim, Germany) to detect anti-N total Ig against the original Wuhan strain on the Roche Cobas e411 platform. The results of anti-N total Ig antibodies were evaluated using the manufacturer’s initial cut-off index (COI) of 1.0. The number of infections was estimated based on the number of individuals who tested positive for total anti-N Ig and/or had a history of COVID-19 infection.

Chansaenroj J., Suntronwong N., Kanokudom S., Assawakosri S., Vichaiwattana P., Klinfueng S., Wongsrisang L., Thongmee T., Aeemjinda R., Khanarat N., Srimuan D., Thatsanathorn T., Yorsaeng R., Katanyutanon A., Thanasopon W., Bhunyakitikorn W., Sonthichai C., Angsuwatcharakorn P., Withaksabut W., Wanlapakorn N., Sudhinaraset N, & Poovorawan Y. (2023). Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023. Scientific Reports, 13, 15595.

+ Open protocol

+ Expand

Biomarkers in Cardiovascular Risk

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were collected on the same day of the medical visit. Patients were instructed to fast overnight and not to take any medications before blood sampling on the morning of the tests. Blood samples were drawn after a 30 min supine rest. The following analyses were performed: high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), NT-proBNP, Hb1Ac, and uric acid. Hs-CRP was measured with a quantitative turbidimetric test (TRUEchemie). NT-proBNP was measured with the ECLIA monoclonal assay using the Cobas e411 platform (Roche Diagnostics Italia, Monza, Italy). Plasma norepinephrine was evaluated using high-performance liquid chromatography with the electrochemical detector CLC 100 (Chromsystems, Munchen, Germany). Interleukin-6 was measured with an in vitro enzyme-linked immunosorbent assay for quantitative measurement (RayBiotech IL-6 ELISA kit).

Balletti A., De Biase N., Del Punta L., Filidei F., Armenia S., Masi F., Di Fiore V., Mazzola M., Bacca A., Dini F.L., Taddei S., Masi S, & Pugliese N.R. (2023). Cardiometabolic Phenotyping in Heart Failure: Differences between Patients with Reduced vs. Preserved Ejection Fraction. Diagnostics, 13(4), 790.

+ Open protocol

+ Expand

Hepatitis Screening in HIV Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

People attending Kiruddu National Referral Hospital (Kampala) for routine HIV care once per week (Fridays) were consecutively invited to participate in the study. After informed consent, samples were collected on the PSC from capillary whole blood and were allowed to dry for a minimum of 4 h, following the manufacturer's protocol. Participants received a reimbursement for their transportation costs to attend the hospital. Samples were collected by trained laboratory staff, labelled with patient identifiers, dried for four hours using the drying rack, packed and transferred at the end of the day to the Central Public Health Laboratory (CPHL). Uganda has a centralized reference testing laboratory for viral hepatitis where all serology and molecular analyses were carried out. HBsAg and anti-HCV were determined with the COBAS®e411 platform (Roche Diagnostics) and all reactive samples were then analysed for HBV-DNA and HCV-RNA on the COBAS® 4800 (Roche Diagnostics).

Picchio C.A., Nicolàs A., Ayemfouo Fofou I.V., Kasone V., Guewo-Fokeng M., Tagny C.T., Nanyonjo T., Nansumba H., Kouongni Y.N., Sezawo Kamdjeu R.G.E., Seremba E., Kouanfack C., Ssewanyana I., Njouom R., Segura A.R., Rodríguez-Frías F., Mbanya J.C., Ocama P, & Lazarus J.V. (2024). Acceptability and Feasibility of the Plasma Separation Card for an Integrated Model of Care for HBV and HCV Screening Among People Attending HIV Clinics in Cameroon and Uganda. Journal of epidemiology and global health.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!